secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001804220-24-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q1 revenue down 1% to $3.15B; Non-GAAP EPS $9.55; new $3B buyback
---------------------------------------------------------------------------

- GAAP net income $722M ($6.27 diluted EPS) vs $818M ($7.17) YoY; Non-GAAP net income $1,116M ($9.55).
- Dupixent global net sales up 24% to $3.08B; EYLEA HD U.S. sales $200M, total EYLEA/HD $1.4B (down 2%).
- Libtayo global net sales up 45% to $264M; Sanofi collaboration revenue up 14% to $910M.
- Board authorized new $3.0B share repurchase; Q1 repurchases $298M, $1.2B remaining under prior program.
- 2024 guidance updated: GAAP R&D $4.92-5.17B, GAAP SG&A $2.94-3.09B; gross margin unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422024000015/0001804220-24-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422024000015/regn-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001804220-24-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer